Previous 10 | Next 10 |
Marker Therapeutics, Inc. (MRKR) Q3 2020 Earnings Conference Call November 09, 2020, 17:00 ET Company Participants Anthony Kim - CFO Peter Hoang - President, CEO & Director Mythili Koneru - Chief Medical Officer Juan Vera - Chief Development Officer & Director Conference Call Particip...
Marker Therapeutics (MRKR): Q3 GAAP EPS of -$0.16 misses by $0.02.Cash and equivalents of $27M.The Company raised $2.2M through the previously executed $30M common stock purchase agreement with Aspire Capital Fund and remaining $27.8M available to Marker from Aspire Capital along with current...
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - Initiated first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled the first patient in the safety lead-in portion - - Re...
Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020 PR Newswire HOUSTON, Nov. 2, 2020 HOUSTON , Nov. 2, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), ...
HOUSTON , Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indication...
Marker Therapeutics (NASDAQ: MRKR ) : Q2 GAAP EPS of -$0.14 in-line. Cash and equivalents $32.1M Press Release More news on: Marker Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
HOUSTON , Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today...
HOUSTON , June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indica...
HOUSTON , June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, ...
"The most pathetic person in the world is someone who has sight, but has no vision ." - Helen Keller Equities continued to move ahead this week. Investors seem more and more confident that the massive and unprecedented stimulus provided by both Congress and the Federal Reserve will make t...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...